Q2 Earnings Estimate for Danaher Issued By Leerink Partnrs

Danaher Co. (NYSE:DHR) – Analysts at Leerink Partnrs reduced their Q2 2025 earnings per share (EPS) estimates for shares of Danaher in a research report issued to clients and investors on Wednesday, January 29th. Leerink Partnrs analyst P. Souda now anticipates that the conglomerate will earn $1.74 per share for the quarter, down from their prior forecast of $1.88. The consensus estimate for Danaher’s current full-year earnings is $8.15 per share. Leerink Partnrs also issued estimates for Danaher’s Q3 2025 earnings at $1.85 EPS.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.14. Danaher had a return on equity of 10.72% and a net margin of 16.33%. During the same quarter in the prior year, the business posted $2.09 earnings per share.

Other equities research analysts also recently issued reports about the stock. TD Cowen lifted their price target on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. JPMorgan Chase & Co. decreased their price objective on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a research note on Tuesday. Scotiabank assumed coverage on Danaher in a research note on Monday, December 23rd. They set a “sector perform” rating and a $265.00 target price for the company. KeyCorp lifted their price target on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Finally, StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. Six equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $278.00.

Danaher Trading Down 0.3 %

Shares of Danaher stock opened at $223.16 on Friday. Danaher has a 52-week low of $221.34 and a 52-week high of $281.70. The stock has a market cap of $161.19 billion, a PE ratio of 42.27, a PEG ratio of 4.22 and a beta of 0.83. The firm has a 50-day moving average of $235.89 and a 200-day moving average of $253.45. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37.

Institutional Trading of Danaher

Several institutional investors have recently made changes to their positions in the company. Heck Capital Advisors LLC bought a new position in shares of Danaher during the 4th quarter worth approximately $27,000. Decker Retirement Planning Inc. bought a new position in Danaher in the 4th quarter valued at $31,000. Golden State Wealth Management LLC purchased a new position in shares of Danaher in the 4th quarter worth about $31,000. Teachers Insurance & Annuity Association of America bought a new stake in Danaher in the third quarter worth about $39,000. Finally, MidAtlantic Capital Management Inc. purchased a new position in Danaher in the third quarter valued at approximately $40,000. Institutional investors own 79.05% of the company’s stock.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.48%. The ex-dividend date is Friday, December 27th. Danaher’s payout ratio is currently 20.45%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.